Premium
The Effect of Orlistat, an Inhibitor of Dietary Fat Absorption, on the Absorption of Vitamins A and E in Healthy Volunteers
Author(s) -
Melia Angela T.,
KossTwardy Susan G.,
Zhi Jianguo
Publication year - 1996
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1996.tb04230.x
Subject(s) - orlistat , placebo , pharmacokinetics , vitamin , crossover study , medicine , oral administration , absorption (acoustics) , endocrinology , fat soluble vitamin , vitamin e , obesity , chemistry , weight loss , antioxidant , biochemistry , physics , alternative medicine , pathology , acoustics
An open‐label, placebo‐controlled, randomized, two‐way crossover study was performed in 12 healthy volunteers (between 20 and 44 years of age) to assess the effect of orlistat, a gastrointestinal lipase inhibitor that reduces dietary fat absorption and is being developed for weight control in obesity, on the absorption of vitamins A and E. Each participant received a single oral dose of 25,000 IU vitamin A followed 24 hours later by a single oral dose of 400 IU vitamin E on two separate occasions: during oral administration of 120 mg orlistat or placebo three times daily for 9 days. The two treatments were separated by a washout period of at least 2 weeks. Serial blood samples for pharmacokinetic analysis were collected at specified times over 24 hours after each dose of vitamin A for determination of serum concentrations of retinol, and over a period of 5 days after each dose of vitamin E for determination of serum concentrations of α‐tocopherol, total cholesterol, and triglycerides. Orlistat significantly reduced the absorption of vitamin E (∼43% according to maximum concentration and ∼60% according to area under the concentration‐time curve), but not that of vitamin A, at the dose levels studied. The results of this study will aid in the implementation of a vitamin supplementation strategy, should vitamin deficiency occur in patients undergoing orlistat therapy .